Westfield Capital Management Co. LP acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 41,515 shares of the biopharmaceutical company’s stock, valued at approximately $5,096,000.
Several other institutional investors also recently made changes to their positions in the stock. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in shares of Gilead Sciences by 52.1% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after purchasing an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. lifted its position in shares of Gilead Sciences by 249.1% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after purchasing an additional 7,168 shares during the last quarter. NewEdge Wealth LLC lifted its position in shares of Gilead Sciences by 2.9% during the 3rd quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock worth $75,962,000 after purchasing an additional 17,284 shares during the last quarter. Nordea Investment Management AB lifted its position in shares of Gilead Sciences by 16.5% during the 4th quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after purchasing an additional 726,101 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Gilead Sciences by 4.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 161,155 shares of the biopharmaceutical company’s stock worth $17,888,000 after purchasing an additional 6,680 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the sale, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 68,000 shares of company stock worth $9,047,570. Company insiders own 0.30% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Analysis on Gilead Sciences
Gilead Sciences News Summary
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Citi and Scotiabank both reiterated bullish views on Gilead, with each firm maintaining a Buy rating, which can support investor confidence in the stock. Gilead Sciences (GILD) Receives a Buy from Citi
- Positive Sentiment: Gilead highlighted progress on lenacapavir in South Africa, where the government and Global Fund are accelerating access to the HIV prevention drug, reinforcing the company’s growth story in HIV. Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the inflammation/autoimmune pipeline around gamgertamig, a potential first-in-class T cell engager. Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Positive Sentiment: Gilead’s inclusion in a list of “best quality growth stocks” may add to the market’s view that the company remains a high-quality large-cap healthcare name. 5 Best Quality Growth Stocks to Buy
- Neutral Sentiment: Industry-wide biopharma M&A remains active, and Gilead was mentioned among the sector’s deal-making leaders, which keeps takeover speculation and pipeline deal optionality in focus. Gilead, Merck, Eli Lilly Lead $106 Billion Biopharma Takeover Wave In 2026
- Neutral Sentiment: Gilead also reported a clinical milestone in its IDEAL PBC trial, which could become a future catalyst if the study continues to progress positively. Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst
Gilead Sciences Trading Down 0.0%
Gilead Sciences stock opened at $129.16 on Friday. The business has a 50 day moving average price of $134.38 and a two-hundred day moving average price of $134.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The stock has a market cap of $160.36 billion, a price-to-earnings ratio of 17.60 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current year.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.
Gilead Sciences Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- MarketBeat Week in Review – 06/01 – 06/05
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
